CN114948939A - Application of parthenolide in preparation of auxiliary anticancer drugs - Google Patents
Application of parthenolide in preparation of auxiliary anticancer drugs Download PDFInfo
- Publication number
- CN114948939A CN114948939A CN202210472893.4A CN202210472893A CN114948939A CN 114948939 A CN114948939 A CN 114948939A CN 202210472893 A CN202210472893 A CN 202210472893A CN 114948939 A CN114948939 A CN 114948939A
- Authority
- CN
- China
- Prior art keywords
- parthenolide
- preparation
- anticancer drug
- production process
- dexamethasone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BUQLXKSONWUQAC-UHFFFAOYSA-N Parthenolide Natural products CC1C2OC(=O)C(=C)C2CCC(=C/CCC1(C)O)C BUQLXKSONWUQAC-UHFFFAOYSA-N 0.000 title claims abstract description 65
- KTEXNACQROZXEV-PVLRGYAZSA-N parthenolide Chemical compound C1CC(/C)=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 KTEXNACQROZXEV-PVLRGYAZSA-N 0.000 title claims abstract description 65
- 229940069510 parthenolide Drugs 0.000 title claims abstract description 65
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 20
- 229940041181 antineoplastic drug Drugs 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims description 12
- 230000000694 effects Effects 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 14
- 230000002708 enhancing effect Effects 0.000 claims abstract description 11
- 230000005764 inhibitory process Effects 0.000 claims abstract description 11
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 9
- 229940044683 chemotherapy drug Drugs 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims abstract description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 40
- 229960003957 dexamethasone Drugs 0.000 claims description 40
- 208000032839 leukemia Diseases 0.000 claims description 39
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 230000001093 anti-cancer Effects 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000003825 pressing Methods 0.000 claims description 2
- 238000007670 refining Methods 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 44
- 238000005516 engineering process Methods 0.000 description 10
- 230000006907 apoptotic process Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 7
- 230000009545 invasion Effects 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 240000004460 Tanacetum coccineum Species 0.000 description 1
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000040 effect on leukemia Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 229930009674 sesquiterpene lactone Natural products 0.000 description 1
- -1 sesquiterpene lactone compound Chemical class 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to an application of parthenolide in preparing an auxiliary anticancer drug, in particular to an application of parthenolide in preparing a drug for enhancing the tumor cell inhibition effect of a chemotherapy drug, and provides a new application direction of the anticancer drug.
Description
Technical Field
The invention relates to the field of medicine, in particular to application of parthenolide in preparation of an auxiliary anticancer drug.
Background
Cancer is a persistent disease that seriously harms human health and has now become the second leading killer to cardiovascular diseases. Since the 21 st century, the incidence of leukemia is on the rise year by year due to the rapid progress of modern industrialization and many factors such as environmental pollution. Leukemia is a hematologic malignancy caused by heterogeneous cloning of bone marrow hematopoietic stem cells and is characterized by abnormal proliferation of bone marrow precursor cells, resulting in a range of symptoms including anemia, bleeding, fever and life-threatening infections. Dexamethasone (Dexamethasone, Dex) as a typical glucocorticoid has a strong killing effect on lymphocytes, and is widely used in clinical chemotherapy of hematological tumors. It has been reported that dexamethasone can induce apoptosis of leukemia cells and inhibit proliferation of leukemia cells, but the drug resistance of cancer cells to dexamethasone during chemotherapy limits the curative effect of dexamethasone, so that development of auxiliary anti-cancer drugs is necessary to enhance the inhibitory effect of dexamethasone on leukemia cells.
Parthenolide (PTL) is a sesquiterpene lactone compound extracted from the leaves of feverfew, has certain therapeutic effects in treating skin infections, migraine, arthritis, and the like, and has been clinically proven. In recent years, parthenolide has been increasingly used in the field of tumor research. Studies have shown that parthenolide has strong antitumor activity, can inhibit the proliferation of various tumor cells in vitro and induce apoptosis, such as liver cancer, bile duct cancer, gastric cancer, leukemia cells and the like. The main anti-tumor action mechanism of parthenolide relates to the regulation of the activation of NF-kB and other signal channels and the further inhibition of the biological function of tumor cells, thereby achieving the effect of inhibiting the development of tumors. Thus, parthenolide is a green natural product with great potential for anti-tumor, but no research on the anti-cancer efficacy of dexamethasone increased by parthenolide in the prior art is available.
Disclosure of Invention
In view of the defects in the background art, the invention relates to the application of parthenolide in preparing an auxiliary anticancer drug, researches the influence of parthenolide on the enhancement of the inhibition effect of dexamethasone on leukemia cells, and enhances the clinical curative effect on leukemia.
The invention provides an application of parthenolide in preparing an auxiliary anticancer drug.
Furthermore, the application of the parthenolide in preparing the auxiliary anticancer drug is the application of the parthenolide in preparing the drug for enhancing the tumor cell inhibition effect of the chemotherapy drug.
Further, the concentration of the parthenolide is 5-20 mu mol/L.
Further, the chemotherapeutic drug is dexamethasone.
Further, the tumor cell is leukemia.
Furthermore, the medicament for enhancing the inhibition effect of the chemotherapeutic medicament on the tumor cells is a medicament containing a pharmaceutically effective amount of parthenolide and a pharmaceutically acceptable carrier.
Further, the parthenolide adopts a common pharmaceutical technology which comprises but is not limited to a raw material medicine refining and drying technology, a tablet production technology, a hard capsule production technology, a pressing method soft capsule production technology, a small-volume injection production technology, a large-volume injection production technology, an injection sterile subpackaging production technology or an injection freeze-dried product production technology.
Further, the medicament can be prepared into any pharmaceutically acceptable dosage form.
Further, the dosage form includes, but is not limited to, suspension, emulsion, tablet, capsule, granule, oral liquid, spray, injection.
The invention has the main beneficial effects that:
1. the invention explores the new application of parthenolide in pharmacy and provides a new application direction.
2. The parthenolide can obviously enhance the inhibiting effect of dexamethasone on the survival rate, migration and invasion of leukemia cells and the promoting effect of apoptosis, and has the application of enhancing the therapeutic effect of dexamethasone on the leukemia cells.
3. The parthenolide has been applied to other clinical diseases, which shows that the parthenolide has obvious curative effect and small adverse reaction, and can be applied to the application of enhancing the inhibition effect of dexamethasone on leukemia cells.
4. The preparation method of parthenolide has the advantages of rich raw materials, simple process technology, low cost and low price, and is suitable for wide production.
Drawings
FIG. 1 shows the effect of parthenolide on the viability of leukemic cells;
FIG. 2 is the results of the effect of parthenolide on the viability of dexamethasone for leukemia cells;
FIG. 3 is a graph showing the effect of parthenolide on the migration of leukemia cells;
FIG. 4 is the results of the effect of parthenolide on the invasion of leukemia cells by dexamethasone;
FIG. 5 is a graph showing the effect of parthenolide on the apoptosis of leukemia cells by dexamethasone.
Detailed Description
While the embodiments of the present invention will be described and illustrated in detail with reference to the accompanying drawings, it is to be understood that the invention is not limited to the specific embodiments disclosed, but is intended to cover various modifications, equivalents, and alternatives falling within the scope of the invention as defined by the appended claims.
For the convenience of understanding the embodiments of the present invention, the following description will be further explained by taking specific embodiments as examples with reference to the drawings, and the embodiments are not to be construed as limiting the embodiments of the present invention.
The embodiment 1 of the invention relates to the effect of parthenolide on the viability of leukemia cells, and the specific experimental method is as follows:
3*10 3 the method comprises the steps of respectively inoculating the chronic myelogenous leukemia K562 cells and the acute myelogenous leukemia HL-60 cells into a 96-well plate, respectively adding parthenolide (1, 2.5, 5, 10, 20, 40 mu mol/L) with different concentrations, culturing for 48h, and detecting the absorbance of the cells on an enzyme-linked detector by adopting a CCK-8 method. And calculating the inhibition rate of parthenolide on the leukemia cell to be tested.
The results are shown in FIG. 1, and the parthenolide inhibits the absorbance of leukemia cells at concentrations greater than 2.5. mu. mol/L; indicating that parthenolide has utility in the treatment of leukemia.
The embodiment 2 of the invention relates to the effect of parthenolide on the influence of dexamethasone on the survival rate of leukemia cells, and the specific experimental method is as follows:
3*10 3 respectively inoculating the individual chronic myelogenous leukemia K562 cells and the acute myelogenous leukemia HL-60 cells in a 96-well plate, respectively adding different concentrations of 500 mu mol/L dexamethasone, orOne added parthenolide (5, 10, 20. mu. mol/L) and 500. mu. mol/L dexamethasone simultaneously. After the culture is continued for 48h, the absorbance of the cells is detected on an enzyme-linked detector by adopting a CCK-8 method.
The results are shown in figure 2, dexamethasone reduces the absorbance of the leukemia cells, and parthenolide further reduces the absorbance of the leukemia cells after dexamethasone treatment; the application of the parthenolide in enhancing the inhibition effect of dexamethasone on the activity rate of leukemia cells is proved.
Embodiment 3 of the invention relates to the effect of parthenolide on the influence of dexamethasone on leukemia cell migration, and the specific experimental method is as follows:
leukemia cells K562 and HL-60 respectively receive 500 mu mol/L dexamethasone to be treated for 48h independently or simultaneously receive 500 mu mol/L dexamethasone and parthenolide (5, 10, 20 mu mol/L) to be treated for 48h, and then the migration rate of the cells is detected by adopting a scratching experiment.
The results are shown in fig. 3, dexamethasone reduced the mobility of leukemia cells, parthenolide further reduced the mobility of leukemia cells after dexamethasone treatment; the application of the parthenolide in enhancing the inhibition effect of dexamethasone on the migration of leukemia cells is demonstrated.
Embodiment 4 of the invention relates to the effect of parthenolide on the influence of dexamethasone on the invasion of leukemia cells, and the specific experimental method is as follows:
leukemia cells K562 and HL-60 are respectively treated with 500 mu mol/L dexamethasone for 48h or treated with 500 mu mol/L dexamethasone and parthenolide (5, 10, 20 mu mol/L) for 48h, and then the invasion rate of the cells is detected by adopting a Transwell experiment.
The results are shown in fig. 4, dexamethasone reduces the invasion rate of leukemia cells, and parthenolide further reduces the invasion rate of leukemia cells after dexamethasone treatment; the application of the parthenolide in enhancing the effect of dexamethasone on inhibiting the invasion of leukemia cells is shown.
after leukemia cells K562 and HL-60 are respectively treated with 500 mu mol/L dexamethasone for 48h or treated with 500 mu mol/L dexamethasone and parthenolide (5, 10, 20 mu mol/L) for 48h, the apoptosis rate of the cells is detected by flow cytometry.
The results are shown in fig. 5, dexamethasone increases the apoptosis rate of leukemia cells, and parthenolide further increases the apoptosis rate of leukemia cells after dexamethasone treatment; the application of the parthenolide in enhancing the promotion effect of dexamethasone on the apoptosis of leukemia cells is proved.
The compounds, uses and methods of the invention have been described by specific examples. The invention can be used for other purposes by those skilled in the art by appropriately changing the raw materials, the process conditions and the like without departing from the content of the invention, and all similar substitutes and modifications obvious to those skilled in the art are deemed to be included in the scope of the invention
Finally, it should be noted that: the above-mentioned embodiments are only specific embodiments of the present invention, which are used for illustrating the technical solutions of the present invention and not for limiting the same, and the protection scope of the present invention is not limited thereto, although the present invention is described in detail with reference to the foregoing embodiments, those skilled in the art should understand that: any person skilled in the art can modify or easily conceive the technical solutions described in the foregoing embodiments or equivalent substitutes for some technical features within the technical scope of the present disclosure; such modifications, changes or substitutions do not depart from the spirit and scope of the embodiments of the present invention, and they should be construed as being included therein. Therefore, the protection scope of the present invention shall be subject to the protection scope of the claims.
Claims (9)
1. Use of parthenolide in preparing auxiliary anticancer medicine is provided.
2. Use of parthenolide according to claim 1 in the preparation of an adjunctive anticancer drug characterized in that: the application of parthenolide in preparing the auxiliary anticancer drug is the application of parthenolide in preparing the drug for enhancing the tumor cell inhibition effect of the chemotherapy drug.
3. Use of parthenolide according to claim 2 in the preparation of an adjunctive anticancer drug characterized in that: the concentration of the parthenolide is 5-20 mu mol/L.
4. Use of parthenolide according to claim 3 in the preparation of an adjunctive anticancer drug characterized in that: the chemotherapeutic drug is dexamethasone.
5. Use of parthenolide according to claim 3 or 4 in the preparation of an adjunctive anticancer drug characterized in that: the tumor cell is leukemia.
6. Use of parthenolide according to claim 5 in the preparation of an adjunctive anticancer drug characterized in that: the medicament for enhancing the inhibition effect of the chemotherapeutic medicament on the tumor cells contains pharmaceutically effective amount of parthenolide and pharmaceutically acceptable carriers.
7. The use of parthenolide according to claim 6 in the preparation of an adjunctive anticancer drug characterized in that: the parthenolide adopts a common pharmaceutical process including but not limited to a raw material medicine refining and drying process, a tablet production process, a hard capsule production process, a pressing soft capsule production process, a small-volume injection production process, a large-volume injection production process, an injection sterile subpackaging production process or an injection freeze-dried product production process.
8. Use of parthenolide according to claim 7 in the preparation of an adjunctive anticancer drug characterized in that: the medicine can be prepared into any pharmaceutically acceptable dosage form.
9. Use of parthenolide according to claim 8 in the preparation of an adjuvant anticancer drug, wherein: the dosage form includes but is not limited to suspension, emulsion, tablet, capsule, granule, oral liquid, spray and injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210472893.4A CN114948939A (en) | 2022-04-29 | 2022-04-29 | Application of parthenolide in preparation of auxiliary anticancer drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210472893.4A CN114948939A (en) | 2022-04-29 | 2022-04-29 | Application of parthenolide in preparation of auxiliary anticancer drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114948939A true CN114948939A (en) | 2022-08-30 |
Family
ID=82978566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210472893.4A Pending CN114948939A (en) | 2022-04-29 | 2022-04-29 | Application of parthenolide in preparation of auxiliary anticancer drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114948939A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102234258A (en) * | 2010-04-23 | 2011-11-09 | 天津尚德药缘科技有限公司 | Preparation method and application of sphaelactone |
| WO2016166761A1 (en) * | 2015-04-14 | 2016-10-20 | Tiltan Pharma Ltd. | Combination therapies and uses thereof in the treatment of cancer |
-
2022
- 2022-04-29 CN CN202210472893.4A patent/CN114948939A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102234258A (en) * | 2010-04-23 | 2011-11-09 | 天津尚德药缘科技有限公司 | Preparation method and application of sphaelactone |
| WO2016166761A1 (en) * | 2015-04-14 | 2016-10-20 | Tiltan Pharma Ltd. | Combination therapies and uses thereof in the treatment of cancer |
Non-Patent Citations (7)
| Title |
|---|
| 何玉婵;周思瑶;唐荣芳;农庆伟;蒋端凤;王晓桃;: "小白菊内酯干预骨髓基质细胞对Jurkat细胞黏附作用的影响及其机制研究", 中国全科医学, no. 05, pages 1 - 4 * |
| 宋培燕: "白血病干细胞介导的白血病耐药性及小白菊内酯的干预作用", 《北方药学》, vol. 01, 1 January 2016 (2016-01-01) * |
| 宋培燕;刘倩平;章志福;魏涛;: "白血病干细胞介导的白血病耐药性及小白菊内酯的干预作用", 北方药学, no. 01 * |
| 张守信等主编: "《现代临床实用诊疗学》", 31 July 2009, pages: 309 * |
| 易娟;陈静;孙静;魏虎来;石建功;: "小白菊内酯对白血病K562细胞及其干细胞的作用", 中国中药杂志, no. 02, pages 1 - 2 * |
| 王晓桃, 刘玲, 刘健等.: "小白菊内酯增强阿霉素和地塞米松对Jurkat白血病细胞增殖抑制及凋亡的研究", 《 时珍国医国药》, vol. 25, pages 1 - 3 * |
| 陈静: "小白菊内酯对白血病K562细胞及其干细胞的作用", 《中国中药杂志》, vol. 02, 15 January 2011 (2011-01-15) * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cheng et al. | Triterpenes from Poria cocos suppress growth and invasiveness of pancreatic cancer cells through the downregulation of MMP-7 Erratum in/ijo/44/5/1781 | |
| Sun et al. | Lentinan reduces tumor progression by enhancing gemcitabine chemotherapy in urothelial bladder cancer | |
| Zhu et al. | Deoxyshikonin isolated from Arnebia euchroma inhibits colorectal cancer by down-regulating the PI3K/Akt/mTOR pathway | |
| Abdel-Salam et al. | Cytotoxicity of Luffa cylindrica (L.) M. Roem. extract against circulating cancer stem cells in hepatocellular carcinoma | |
| Cheng et al. | The effects of polysaccharides from the root of Angelica sinensis on tumor growth and iron metabolism in H22-bearing mice | |
| Lee et al. | Ginsenoside metabolite compound K differentially antagonizing tumor necrosis factor-α-induced monocyte–endothelial trafficking | |
| AU2021246790B9 (en) | Anti-tumor composition containing rare ginsenosides Rk2, CK, and PPT | |
| JP2021130670A (en) | Composition for preventing or treating hepatitis containing monoacetyl diacylglycerol compound | |
| CN109010618B (en) | Traditional Chinese medicine composition with anti-tumor effect and preparation method and application thereof | |
| Yamamoto et al. | Effect of piceatannol-rich passion fruit seed extract on human glyoxalase I–mediated cancer cell growth | |
| Zhang et al. | Ginseng polysaccharide serves as a potential radiosensitizer through inducing apoptosis and autophagy in the treatment of osteosarcoma | |
| Tang et al. | Ginsenoside 3β-O-Glc-DM (C3DM) enhances the antitumor activity of Taxol on Lewis lung cancer by targeting the interleukin-6/Jak2/STAT3 and interleukin-6/AKT signaling pathways | |
| Bao et al. | Scutellarin exerts anticancer effects on human leukemia cells via induction of Sub-G1 cell cycle arrest, apoptosis and also inhibits migration and invasion by targeting Raf/MEK/ERK signalling pathway | |
| CN102614170A (en) | Application of artemisinin B in preparation of antitumor drugs | |
| Chen et al. | Sini decoction inhibits tumor progression and enhances the anti-tumor immune response in a murine model of colon cancer | |
| CN114948939A (en) | Application of parthenolide in preparation of auxiliary anticancer drugs | |
| CN102688489A (en) | Pharmaceutical composition containing triptolide, triptolide derivative and Bc1-2 inhibitor and application thereof | |
| TWI444189B (en) | Use of lanosta-8,24-dien-3β,15α,21-triol for inhibition of tumor cell growth | |
| EP4122480A1 (en) | Use of astragalus medicinal composition for preparing drug for enhancing cancer therapy | |
| Hu et al. | Curcumin inhibits proliferation and invasion of papillary thyroid carcinoma cells by inhibiting the JAK2/STAT3 pathway | |
| CN110092797B (en) | Clerodane diterpenoid compounds and application thereof in pharmacy | |
| CN113116935A (en) | Toad skin sterene total lactone extract and its preparation method and use | |
| CN109045052B (en) | Pharmaceutical formulation for treating colon cancer and application | |
| US20140294753A1 (en) | Novel use of ganodermic acids for treating cancer | |
| Kabir et al. | Anti-cancer efficacy of metformin: recent updates on breast and other cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |